Skip to Content
Merck
All Photos(1)

Documents

Safety Information

Y0000016

Propofol

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

2,6-Diisopropylphenol, 2,6-Bis(1-methylethyl)phenol, 2,6-Bis(isopropyl)phenol, Propofol

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
[(CH3)2CH]2C6H3OH
CAS Number:
2078-54-8
Molecular Weight:
178.27
MDL number:
MFCD00008885
UNSPSC Code:
41116107
PubChem Substance ID:
329830815
NACRES:
NA.24

grade

pharmaceutical primary standard

vapor pressure

5.6 mmHg ( 100 °C)

API family

propofol

manufacturer/tradename

EDQM

refractive index

n20/D 1.514 (lit.)

bp

256 °C/764 mmHg (lit.)

mp

18 °C (lit.)

density

0.962 g/mL at 25 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(C)c1cccc(C(C)C)c1O

InChI

1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3

InChI key

OLBCVFGFOZPWHH-UHFFFAOYSA-N

Gene Information

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Propofol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0000017

Propofol for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0000018

Propofol impurity J, European Pharmacopoeia (EP) Reference Standard

1572503

Propofol, United States Pharmacopeia (USP) Reference Standard

1572547

Propofol Related Compound B, United States Pharmacopeia (USP) Reference Standard

1572525

Propofol Resolution Mixture, United States Pharmacopeia (USP) Reference Standard

1572558

Propofol Related Compound C, United States Pharmacopeia (USP) Reference Standard

1572536

Propofol Related Compound A, United States Pharmacopeia (USP) Reference Standard

BP1031

Propofol, British Pharmacopoeia (BP) Reference Standard

BP698

3,3′-5,5′-Tetraisopropyldiphenol, British Pharmacopoeia (BP) Reference Standard

BP1032

Propofol impurity J, British Pharmacopoeia (BP) Reference Standard

PHR9035

4-Isopropylphenol, reference material

PHR9049

4-Hydroxy-3,5-bis(1-methylethyl)benzoic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR9062

1-(1-Methylethoxy)-2-(1-methylethyl)benzene, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR9074

2,2-Dimethyl-4-(1-methylethyl)-1,3-benzodioxole, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR2565

Propofol Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2566

Propofol Related Compound B

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H315,H319,H335

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

235.4 °F - closed cup

Flash Point(C)

113 °C - closed cup

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

FSL

Group 4: Flammable liquids
Type 3 petroleums
Hazardous rank III
Water insoluble liquid

JAN Code

Y0000016-1EA:
Y0000016-290MG:
Y0000016:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Cynthia Ménard et al.
Radiology, 274(1), 181-191 (2014-09-10)
To determine if the integration of diagnostic magnetic resonance (MR) imaging and MR-guided biopsy would improve target delineation for focal salvage therapy in men with prostate cancer. Between September 2008 and March 2011, 30 men with biochemical failure after radiation
Emily Black et al.
The Annals of pharmacotherapy, 47(6), 856-868 (2013-05-23)
To evaluate the efficacy and safety of propofol compared to other agents for procedural sedation of adults in the emergency department (ED) and to review the use of opioids in conjunction with propofol for procedural sedation in the ED. PubMed
A J Thomson et al.
Anaesthesia, 69(5), 420-428 (2014-04-18)
Debate continues over the most appropriate blood-brain equilibration rate constant (ke0) for use with the Marsh pharmacokinetic model for propofol. We aimed to define the optimal ke0 value. Sixty-four patients were sedated with incremental increases in effect-site target concentration of
Muhammad Suleman Khan et al.
Basic & clinical pharmacology & toxicology, 115(6), 565-570 (2014-06-04)
A variety of techniques have been developed to monitor the depth of anaesthesia. Propofol's pharmacokinetics and response vary greatly, which might be explained by genetic polymorphisms. We investigated the impact of genetic variations on dosage, anaesthetic depth and recovery after
S Bache et al.
British journal of anaesthesia, 110(5), 741-746 (2012-12-22)
Over a 5 yr period, we have encountered three patients in whom remifentanil appeared to have no clinical effect during general anaesthesia (GA). We describe seven anaesthetics in these three patients. We reviewed the literature on this subject. A simple
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service